Stay in touch
Prime news from our network.
#read
Seamless Therapeutics presents groundbreaking data on precise reprogramming of large serine recombinases in the human genome at ESGCT
Seamless Therapeutics has presented new preclinical data on its precise genome editing technology at the European Society for Gene and Cell Therapy (ESGCT) Congress. The results presented show that the company is able to reprogramme large serine recombinases (LSRs) to efficiently and precisely integrate gene-sized DNA fragments into the human genome independently of natural DNA repair mechanisms. In preclinical studies, the LSRs showed high activity in human cells and precise DNA integration.
22/10/2024
Another focus is on zinc finger-dependent recombinases that ensure high target specificity and only become active at the intended sites. CEO Albert Seymour explained that these advances have the potential to create a new class of therapeutics for diseases with high unmet need. In the short term, the company plans to apply these technologies in in vivo models to advance clinical development. The innovations presented position Seamless at the forefront of gene editing technologies.
Source: Seamless Therapeutics from 22 October 2024The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.